行情

MBRX

MBRX

Moleculin
NASDAQ

实时行情|Nasdaq Last Sale

0.9400
+0.0160
+1.73%
盘后: 0.9400 0 0.00% 16:23 01/24 EST
开盘
0.9500
昨收
0.9240
最高
0.9500
最低
0.9000
成交量
25.13万
成交额
--
52周最高
3.150
52周最低
0.7772
市值
4,298.40万
市盈率(TTM)
-2.6089
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MBRX 新闻

  • 红杉中国致信成员企业:坚定信心、砥砺前行
  • 新浪财经.2小时前
  • 波音777X完成首飞:明年起开始交付 未来世界最大客机
  • IT之家.3小时前
  • 瑞幸咖啡捐赠1000万元 助力疫情防控
  • 新浪科技.3小时前
  • 贝索斯手机遭入侵 手机窃听再次成为焦点
  • 新浪科技.4小时前

更多

所属板块

制药
-1.85%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

MBRX 简况

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
展开

Webull提供Moleculin Biotech Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。